Chimeric antigen receptor-modified NK cells target breast carcinomas resistant to soluble antibody treatment
- Weitere Titel
-
Chimäre-antigen-rezeptor-modifizierte NK-Zellen erreichen antikörperbehandlungsresistente Brustkarzinome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Ursprünglich als Dissertation veröffentlicht, Entzug des Doktorgrades durch Bescheid des Präsidenten der FU, bestandskräftg seit: 22.08.2014.
- Schlagwort
-
Killer cells
- Ereignis
-
Veröffentlichung
- (wo)
-
Berlin
- (wer)
-
Freie Universität Berlin
- (wann)
-
2010
- Urheber
- DOI
-
10.17169/refubium-15168.2
- URN
-
urn:nbn:de:kobv:188-refubium-10970.2-6
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:48 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Alsamah, Wisam
- Freie Universität Berlin
Entstanden
- 2010
Ähnliche Objekte (12)
Targeting transcriptional regulators for the treatment of therapy resistant carcinomas
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
The molecular tweezer CLR01 inhibits antibody-resistant cell-to-cell spread of human cytomegalovirus
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity
Café soluble
Human lung carcinomas synthesize immunoregulatory glucocorticoids
Human lung carcinomas express Fas ligand
Sensing of soluble molecules with adapter chimeric antigen receptors for the controllable activation of T cells in an immunosuppressive subcutaneous solid tumor model
Optimization of chimeric antigen receptor (CAR) therapy
Antibody engineering
Antibody therapeutics
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
Targeting transcriptional regulators for the treatment of therapy resistant carcinomas
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
The molecular tweezer CLR01 inhibits antibody-resistant cell-to-cell spread of human cytomegalovirus
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity
Café soluble
Human lung carcinomas synthesize immunoregulatory glucocorticoids
Human lung carcinomas express Fas ligand
Sensing of soluble molecules with adapter chimeric antigen receptors for the controllable activation of T cells in an immunosuppressive subcutaneous solid tumor model
Optimization of chimeric antigen receptor (CAR) therapy
Antibody engineering
Antibody therapeutics
Radiolabeling of anti-EGFR antibody, Cetuximab, overcomes the radiotherapy resistance of Cetuximab resistant head and neck cancer cells
Targeting transcriptional regulators for the treatment of therapy resistant carcinomas
Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity
The molecular tweezer CLR01 inhibits antibody-resistant cell-to-cell spread of human cytomegalovirus
Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity
Café soluble
Human lung carcinomas synthesize immunoregulatory glucocorticoids
Human lung carcinomas express Fas ligand
Sensing of soluble molecules with adapter chimeric antigen receptors for the controllable activation of T cells in an immunosuppressive subcutaneous solid tumor model
Optimization of chimeric antigen receptor (CAR) therapy
Antibody engineering
Antibody therapeutics